Erratum: Candidate genes for the progression of malignant gliomas identified by microarray analysis by Bozinov, Oliver et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
Erratum: Candidate genes for the progression of malignant gliomas
identified by microarray analysis
Bozinov, Oliver; Köhler, Sylvia; Samans, Birgit; Benes, Ludwig; Miller, Dorothea; Ritter, Markus; Sure,
Ulrich; Bertalanffy, Helmut
DOI: https://doi.org/10.1007/s10143-008-0125-9
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-155937
Journal Article
Published Version
Originally published at:
Bozinov, Oliver; Köhler, Sylvia; Samans, Birgit; Benes, Ludwig; Miller, Dorothea; Ritter, Markus; Sure,
Ulrich; Bertalanffy, Helmut (2008). Erratum: Candidate genes for the progression of malignant gliomas
identified by microarray analysis. Neurosurgical Review, 31(2):247-248.
DOI: https://doi.org/10.1007/s10143-008-0125-9
ERRATUM
Candidate genes for the progression of malignant
gliomas identified by microarray analysis
Negative results in the logarithmic M AstroIII/GBM quotient represents upregulation
of the gene
Oliver Bozinov & Sylvia Köhler & Birgit Samans &
Ludwig Benes & Dorothea Miller & Markus Ritter &
Ulrich Sure & Helmut Bertalanffy
Published online: 27 February 2008
# Springer-Verlag 2008
Erratum to: Neurosurg Rev (2008) 31:83-90
DOI 10.1007/s10143-007-0107-3
It was brought to our attention, that there is a misinterpre-
tation of the data in the text of our article [2]. After com-
paring our data with the original ones, we found that the
microarray data as shown in our Table 1 [2] are correct.
However, in the text the column indicating the direction of
expression “down or up” has been mistaken: “down” in this
table refers to a lower expression in anaplastic astrocytomas
(AA) relative to glioblastomas (GBM).
This is consistent with the other values given in the Table.
The median expression levels for both groups were calcu-
lated as mean log2-ratios. A negative result in the logarith-
mic M AstroIII/GBM quotient represents an upregulation of
the gene inGBM. In this regard the direction of the ex-
pression level (FC) in column six can be misleading, but
represents correctly the direction from GBM to AA and not
vice versa, as we erroneously have used in the discussion [2].
Unfortunately, the real-time PCR results in the same
(small) group of tumors did in fact falsely indorse the
misinterpreted results. Recent further investigation in a
larger group of tumors (34 samples) of the same histology
has meanwhile put into perspective the results of IL-13Rα2
and Olig2. Olig2 had an almost 4-fold higher expression in
AA (0,1146) compared to GBM (0,0294) with statistical
significance (p=0,025). IL-13Rα2 showed now a near equal
expression (AA 2,5078, GBM 2,7831) with no statistical
significance. Previous results [1, 5] showed significant
decline of gene expression with tumor grade and lowest
expression of Olig2 in GBM, which is now consistent with
our further analysis and correctly interpreted array results.
The equal expression of IL-13Rα2 in our recent larger PCR
series does not answer satisfactorily the question of
expression differences between AA and GBM.
These differences in real-time PCR quantification com-
pared to the array results make their confirmation insecure.
In similar studies Hoelzinger et al. confirmed only 19 genes
out of 21 by quantitative RT-PCR [3] and van den Boom
et al. in 9 out of 12 cases [6]. According to Vandesompele
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et al. normalization of real-time quantitative RT-PCR data
by geometric averaging of multiple internal control genes
might be the solution and could open the possibility of
studying the biological relevance of small expression
differences [7]. However, small series, such as ours, seam
to be at risk for false confirmation and even further studies
in larger groups can be misleading. Additional tissue based
investigation, such as immunohistochemistry or in situ
hybridization may in future be more valuable to support the
results from the PCR studies
It will be our obligation for the future, to provide profound
data on a large amount of tissue samples and different
quantification methods to clarify these uncertainties and
initial microarray analysis, especially regarding IL-13Rα2,
which plays a critical biologic role in IL-13 cytotoxin-
mediated therapy for GBM [4]. Any possible beneficial role
of this treatment regimen for GBM rather than for AA
needs to be confirmed by a larger series. Accordingly,
clinical trials addressing the prognostic relevance may
highlight the functional significance. The conclusion of
our article regarding the powerful approach of gene
expression profiling to identify transcriptional differences
of significance in gliomas remains [2], but its confirmation
seems challenging and needs expansion to multiple quan-
tification methods in order to avoid interpretation mistakes.
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